Williamson DB, Haltiwanger RS. Identification, function, and biological relevance of POGLUT2 and POGLUT3. Biochem Soc Trans. 2022 Apr 29;50(2):1003-12. doi: 10.1042/BST20210850
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Capdevila Bert R, Marsal Mora JR, Pujol Salud J, Anguera Farran R. Prevalence study of iodine deficiency in a 6-year-old school population. An Pediatr (Barc). 2010 May;72(5):331-8. doi: 10.1016/j.anpedi.2009.12.023
Garcia-Esteve L, Torres A, Navarro P, Aguado J, Ascaso C. Maternidad the planned y psicomorbilidad: un riesgo evitable / Unplanned pregnancy and psychological morbidity: an avoidable risk. Fac Med Barc. 2005 Jul;32(3):111-8.